top of page

Pipeline

Our first product, the TERAH-7 protein, targets pre-cancerous lesions and cancers related to the human papillomavirus, HPV.

SCREEN-immunotherapeutic.png

Effectiveness

ImunoTera's therapeutic vaccine demonstrated synergy with other treatments, such as chemotherapy, with high efficacy in combating HPV-induced cancer, in the preclinical phase.

Product
Technology
Clinical Indication
Idea
Preclinical
First-in-human
Clinical
Phase I
Clinical
Phase II
Clinical
Phase III
HPV / Carcinoma in situ
TERAH-7
Recombinant Protein
HPV / Cervical cancer
of the uterus
HPV / Oropharyngeal Cancer
HPV / Anal Cancer
TERAVID-19
DNA vaccine
SARS-COV-2 / COVID-19
A9Z
monoclonal antibody
ZIKV / DENV
IMT-0124
In definition
HIV/AIDS
IMT-0752
In definition
HER2* breast cancer
IMT-PSK3
In definition
Prostate cancer
bottom of page